1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Jesús CP, Alfonso CS, Belén PM, Jose Antonio DR, Odile AI, Eva María GA, Serrano Domingo JJ.

    Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity.

    CURR ONCOL REP . : .

    [doi:10.1007/s11912-023-01434-0]

  • Salge-Arrieta FJ, Vior-Fernández C, Lee P, Reguero-Callejas ME, Pian-Arias HG, Martínez-San Millán JS, Carrasco-Moro R.

    Giant fronto-spheno-orbitary juvenile psammomatoid ossifying fibroma: Case report and literature review.

    CHILDS NERVOUS SYSTEM . : .

    [doi:10.1007/s00381-023-06206-6]

  • Pena-Burgos EM, Romio De Las Heras E, Bernabéu D, Iglesias-Urraca C, Reguero Callejas ME, Pozo-Kreilinger JJ.

    Giant Cell Tumor of the Rib: A Report of Two Patients.

    INT J SURG PATHOL . : .

    [doi:10.1177/10668969241256119]

  • Guerrero P, Albarrán V, González-Merino C, García de Quevedo C, Sotoca P, Chamorro J, Rosero DI, Barrill A, Alía V, Calvo JC, Moreno J, Pérez de Aguado P, Álvarez-Ballesteros P, San Román M, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Guerra E, Martínez-Delfrade Í, Garrido P, Gajate P.

    Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae284]

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does adjuvant mitotane impact cure rates in adrenocortical carcinoma? Insights from the ICARO-GETTHI/SEEN registry.

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : .

    [doi:10.1210/clinem/dgaf082]

  • Araujo-Castro M, Menéndez Torre E, Aida CL, García-Centeno R, González L, Idrobo C, Achote E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín-Rojas P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.

    Validation and limitations of the PANOMEN-3 predictive model for tumor recurrence and progression in pituitary tumors.

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : .

    [doi:10.1210/clinem/dgaf252]

  • Gorospe L, Saavedra-Serrano C, Martínez-Jáñez N.

    Eribulin-induced pulmonary toxicity mimicking metastatic lung disease.

    MEDICINA CLINICA . 165(1): 106993-106993.

    [doi:10.1016/j.medcli.2025.106993]

  • Zamorano M, Ventas-Ayala B, Reguero ME, Sales-Sanz M.

    Fibroadipose vascular anomaly in the orbital region.

    JOURNAL OF AAPOS . : 104222-104222.

    [doi:10.1016/j.jaapos.2025.104222]

  • Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.

    Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.

    Oncology and therapy . : .

    [doi:10.1007/s40487-025-00347-1]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer.

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]

  • Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.

    Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.

    NATURE MEDICINE . : .

    [doi:10.1038/s41591-025-03734-3]